Tradestie Institutional Equity Comparison Engine

ELAN vs TAK โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

TAK Overall Edge

TAK Captures Institutional Edge (3โ€“1 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) driven by superior Valuation, Growth & Margin, Momentum & Technical while ELAN counters with relative strength in Options & Structure. Fundamentally, ELAN trades at 20.8x Forward P/E with 7.7% operating margin (+11.3% YoY revenue) versus TAK at 12.7x Forward P/E and 16.6% operating margin (+6.7% YoY). In options structure, ELAN sits in CONSOLIDATION (1st %ile IV; Dealer Gamma Walls on Pro) against TAK sits in UNCLASSIFIED (5th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner TAK
ELAN 20.8x vs TAK 12.7x Fwd P/E
Growth & Margin Winner TAK
Op Margin 7.7% vs 16.6% ยท YoY +11.3% vs +6.7%
Momentum & Technical Winner TAK
1Y +19.9% vs +51.8% ยท 52W Pos 81% vs 97%
Options & Structure Winner ELAN
CONSOLIDATION (1st %ile IV) vs UNCLASSIFIED (5th %ile IV)
ELAN NYSE
Elanco Animal Health Incorporated Common Stock
Pharmaceutical Preparations
$26.36
-1.59% 1D
Market Cap $13.2B
1M Return +11.91%
1Y Return +19.85%
Forward P/E 20.8x
Unified AI Score
33.1 / 100 SELL
Tech 50.0 Fund 37.0 Flow 71.0 Mom 50.0
TAK NYSE
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Pharmaceutical Preparations
$21.61
+0.86% 1D
Market Cap $67.5B
1M Return +9.89%
1Y Return +51.79%
Forward P/E 12.7x
Unified AI Score
48.0 / 100 HOLD
Tech 43.0 Fund 44.0 Flow 50.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ELAN +19.85% TAK +51.79% Spread: +31.94 pp (TAK Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ELAN TTM Op. Margin: 7.7% TAK TTM Op. Margin: 16.6%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ELAN vs TAK. Trailing 12-month operating profitability (ELAN 7.7% vs TAK 16.6%) and valuation multiples (ELAN 20.8x vs TAK 12.7x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ELAN (2) vs TAK (8)
Institutional Metric ELAN TAK Criterion Row Winner
Market Capitalization Scale $13.2B $67.5B Larger Scale TAK
Trailing P/E Ratio Valuation 19.6x N/M Lower Multiple ELAN
Forward P/E Ratio Valuation 20.8x 12.7x Lower Multiple TAK
Revenue Growth (YoY) Growth +11.3% +6.7% Higher Growth ELAN
Operating Margin (TTM) Profitability 7.7% 16.6% Higher Margin TAK
Net Profit Margin Profitability -2.9% 0.9% Higher Margin TAK
Return on Equity (ROE) Capital Efficiency -2.2% 0.6% Higher ROE TAK
52-Week Range Position Momentum 81% ($19โ€“$28) 97% ($14โ€“$22) Stronger Trend TAK
Beta / 30D Volatility Risk Regime 1.27ฮฒ ยท 49% Vol -0.02ฮฒ ยท 22% Vol Lower Realized Risk TAK
Unified Institutional Score Composite Signal 33.1 / 100 (SELL) 48.0 / 100 (HOLD) Higher Composite TAK

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ELAN vs TAK Buy Guide
ELAN CONSOLIDATION
76d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 1st %ile
IV Regime Compressed (<25th %ile)
Live ELAN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
TAK UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 5th %ile
IV Regime Compressed (<25th %ile)
Live TAK Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ELAN nor TAK registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.